Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

BACKGROUND: Prostate cancer (PC) is one of the most common cancers in men. Although the overall prognosis is favorable, the management of metastatic castration-resistant prostate cancer (mCRPC) patients is challenging. Usually, mCRPC patients with progressive disease are considered for radioligand t...

Descripción completa

Detalles Bibliográficos
Autores principales: Manafi-Farid, Reyhaneh, Harsini, Sara, Saidi, Bahare, Ahmadzadehfar, Hojat, Herrmann, Ken, Briganti, Alberto, Walz, Jochen, Beheshti, Mohsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484081/
https://www.ncbi.nlm.nih.gov/pubmed/33677734
http://dx.doi.org/10.1007/s00259-021-05237-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484081/
https://www.ncbi.nlm.nih.gov/pubmed/33677734
http://dx.doi.org/10.1007/s00259-021-05237-y

Ejemplares similares